Jazz Pharmaceuticals Plc · NASDAQ:JAZZ
Jazz Pharmaceuticals — 33rd Annual J.P. Morgan Healthcare Conference (January 2015)
7 slides from Jazz Pharmaceuticals's conference presentation, Jan 13, 2015
Slide 1: 33rd Annual JP Morgan Healthcare Conference
© Jazz Pharmaceuticals’ 33 Annual JP Morgan Healthcare Conference Bruce Cozadd, Chairman and CEO JANUARY 12, 2015
Slide 2: Forward-Looking Statements
Forward-Looking Statements "Safe Harbor" Statement Under the Private Securities Litigation Reform Act of 1995 This presentation contains forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals’ future growth potential, including its 2014 financial guidan
Slide 3: Growing Diversified Revenues
Growing Diversified Revenues @ Total Revenues! Expect lo Meet Distribution of Worldwide (in millions) Net Product Sales Through 9/30/14 $1,400 + $1,150- $1,200 4 ae? Prialt/Other Defitelio/ $1,000 + defibrotide $872 $800 + $600 4 $586 Erwinaze/ Erwinase $400 4 $272 $200 4 Xyrem $0 4 2011 2012 2013 2
Slide 4: Xyrem: Continued Strong Sales
Xyrem: Continued Strong Sales (in millions) $1,000 5 $750 4 $500 4 $250 4 Volume Growth (YOY%) Expect to Meet Guidance $765 - $780'2 $569" $379! 2012 2013 20146 2012-2013 audited; 2014G unaudited. 2 G=Guidance. Guidance provided by Jazz Pharmaceuticals plc on and as of November 4, 2014. The company
Slide 5: Erwinaze/Erwinase: Building for Success
Erwinaze/Erwinase: Building for Success (do) Expect to Meet (in millions) Guidance $250 + GROWTH INITIATIVES $190 - $2007: Support use in appropriate populations $200 + : * Focus on IV administration, sBLA approved $1741 December 2014 * Generate additional data in YA patients $150 + — Study initiate
Slide 6: Defitelio/defibrotide
Defitelio/defibrotide (in millions, unaudited) 24 $100 $90 $80 $70 $60 $50 $40 $30 $20 $10 $0 $452 2013 Expect to Meet Guidance 2014G = $65-70' Pro forma = $68-732 2014 Jazz Pharmaceuticals ple 2014 Guidance! HE Net sales from historic Gentium S.p.A. © GROWTH INITIATIVES ee Continue EU launch * Focu
Slide 7: 2014 Accomplishments
2014 Accomplishments @ REVENUES/COMMERCIAL Exceeded $1 billion in revenues Xyrem: 10% volume growth rate Defitelio: Initiated EU launch for severe VOD Erwinaze: IV administration sBLA approved CLINICAL DEVELOPMENT JZP-110: Initiated start-up activities for planned Phase 3 trials (EDS in narcolepsy,
Jazz Pharmaceuticals — 33rd Annual J.P. Morgan Healthcare Conference (January 2015) on 6ix